

### This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Drug delivery</b>			
Dendritic cell (DC)-mediated delivery of tacrolimus to autoreactive T cells	<p><i>In vitro</i> and mouse studies suggest DCs could be useful for delivering Prograf to treat autoimmune diseases. In cell culture, DCs treated with Prograf sequestered and slowly released the drug over at least 72 hours. In a mouse model of collagen-induced arthritis, transplantation of DCs previously treated <i>ex vivo</i> with Prograf led to decreased arthritis severity compared with transplantation of untreated cells. Next steps include further defining potential autoantigens and more thorough safety testing. Astellas Pharma Inc. markets Prograf tacrolimus for various transplant and autoimmune indications.</p> <p><b>SciBX 6(7); doi:10.1038/scibx.2013.176</b> Published online Feb. 21, 2013</p>	Patent and licensing status undisclosed	<p>Orange, D.E. <i>et al.</i> <i>eLIFE</i>; published online Feb. 5, 2013; doi:10.7554/eLIFE.00105  <b>Contact:</b> Robert B. Darnell, The Rockefeller University, New York, N.Y.                      e-mail: <a href="mailto:darnelr@rockefeller.edu">darnelr@rockefeller.edu</a>  <b>Contact:</b> Dana E. Orange, same affiliation as above                      e-mail: <a href="mailto:dorange@rockefeller.edu">dorange@rockefeller.edu</a></p>